Scilex Holding Company (SCLX)

0,9514 +0,0536 (+5,97 %) À la clôture : 04:00PM EDT

Scilex Holding Company

960 San Antonio Road
Palo Alto, CA 94303
United States
650 516 4310
https://www.scilexholding.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 105

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Henry H. Ji Ph.D.	Executive Chairman	885,43k	S.O.	1964
Mr. Stephen Ma	Senior VP, CFO & Corporate Secretary	708,78k	S.O.	1973
Mr. Jaisim Shah	President, CEO & Director	785,73k	S.O.	1960
Dr. Suketu D. Desai Ph.D.	CTO & Senior VP	S.O.	S.O.	1966
Ms. Gigi DeGuzman	Executive Director of Administrative Operations & Head of Human Resources	S.O.	S.O.	S.O.
Mr. Steven F. Lincoln J.D.	General Counsel & Chief Compliance Officer	S.O.	S.O.	S.O.
Mr. Sumant Rajendran	Executive Director of Marketing	S.O.	S.O.	S.O.
Mike Ciaffi	National Sales Director	S.O.	S.O.	S.O.
Mr. Suresh K. Khemani	Senior VP & Chief Commercial Officer	456,82k	S.O.	1960
Dr. Dmitri V. Lissin M.D.	Senior VP & Chief Medical Officer	528,83k	S.O.	1960

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Scilex Holding Company en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.